We’re excited to announce that Biocytogen will be attending IMMUNOLOGY 2026 in Boston, MA. This year’s meeting will be centered around Translational Immunology: Innovations to Clinical Impact. Join us for a packed program, featuring major symposia, roundtable talks, lectures, and networking opportunities. Come connect with our team at booth #421 to learn how Biocytogen is driving advancements in immunology!
What is IMMUNOLOGY (AAI) 2026?
The American Association of Immunologists (AAI) hosts the world’s largest annual all-immunology meeting, bringing together scientists from more than 40 countries who are at all career stages— from international leaders to the next generation of scientists. Over 3,500 scientists are expected to attend IMMUNOLOGY 2026 to hear about cutting-edge science and learn of innovations and products that can benefit their research programs.
Event Overview
Date: April 16th - 18th, 2026
Venue: Thomas M. Menino Convention & Exhibition Center, 415 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the schedule overview.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting with you in Boston, MA!
